Cases (n = 232) | Controls (n = 4353) | Unadjusted odds ratio (95% CI) | P value | Adjusted* odds ratio (95% CI) | P value | |
---|---|---|---|---|---|---|
Category of antipsychotic exposure: | ||||||
Current | 195 (84.1%) | 2,956 (67.9%) | 2.91 (1.48 - 5.73) | 0.002 | 2.31 (1.16 - 4.59) | 0.017 |
Recent | 28 (12.1%) | 1,002 (23.0%) | 1.24 (0.58 - 2.64) | 0.585 | 0.96 (0.44 - 2.07) | 0.910 |
Past∫ | 9 (3.9%) | 395 (9.1%) | 1 | 1 | ||
Class of antipsychotic received: (within past 3 months) | ||||||
Conventional only | 53 (22.8%) | 507 (11.6%) | 4.67 (2.27 - 9.61) | <0.001 | 3.52 (1.69 - 7.35) | 0.001 |
Atypical only | 134 (57.8%) | 2,386 (54.8%) | 2.49 (1.26 - 4.93) | 0.009 | 2.01 (1.01 - 4.03) | 0.048 |
Both | 8 (3.4%) | 63 (1.4%) | 5.66 (2.11 - 15.17) | 0.001 | 4.21 (1.53 - 11.59) | 0.005 |
No of antipsychotic scripts received: (within past 3 months) | ||||||
1 | 96 (41.4%) | 1,504 (34.6%) | 2.82 (1.41 - 5.65) | 0.003 | 2.19 (1.08 - 4.42) | 0.029 |
≥2 | 99 (42.7%) | 1,452 (33.4%) | 3.01 (1.5 - 6) | 0.002 | 2.44 (1.21 - 4.93) | 0.013 |
No of different antipsychotic drugs received: (within past 3 months) | ||||||
1 | 178 (76.7%) | 2,857 (65.6%) | 2.74 (1.39 - 5.4) | 0.004 | 2.19 (1.1 - 4.36) | 0.025 |
≥2 | 17 (7.3%) | 99 (2.3%) | 7.68 (3.32 - 17.75) | <0.001 | 5.87 (2.48 - 13.89) | <0.001 |
DDDs: (within past 3 months) | ||||||
<15 | 82 (35.3%) | 1,440 (33.1%) | 2.48 (1.23 - 5) | 0.011 | 1.96 (0.96 - 3.99) | 0.064 |
≥15 | 113 (48.7%) | 1,516 (34.8%) | 3.31 (1.66 - 6.6) | 0.001 | 2.62 (1.3 - 5.25) | 0.007 |
Formulation: (within past 3 months) | ||||||
Oral | 188 (81.0%) | 2,822 (64.8%) | 2.95 (1.5 - 5.81) | 0.002 | 2.34 (1.17 - 4.64) | 0.016 |
Acute injection | 5 (2.2%) | 97 (2.2%) | 2.28 (0.75 - 6.95) | 0.147 | 2.05 (0.66 - 6.37) | 0.215 |
Long-acting injection | 0 (0.0%) | 22 (0.5%) | - | - |